EJMI. 2022; 6(4): 429-435 | DOI: 10.14744/ejmi.2022.79013

Evaluation of Immunotherapy and Targeted Therapies in the Treatment of Metastatic Malignant Melanoma

Ziya Kalkan¹, Senar Ebinc¹, Zuhat Urakci¹, Zeynep Oruc¹, Serdar İıleri¹, Sezai Tunc¹, Mehmet Kucukoner¹, Muhammet Ali Kaplan¹, Abdurrahman Isikdogan^1
1Department of Medical Oncology, Dicle University Medical Faculty, Diyarbakır, Türkiye

Objectives: The prognosis of metastatic malignant melanoma is poor. In this study, we aim to evaluate the response rates, PFS and OS times obtained with Nivolumab, Ipilimumab and Dabrafenib plus Trametinib in the treatment of advanced malignant melanoma, as well as the side effect profiles of these three agents. Methods: This study included 58 patients diagnosed with advanced malignant melanoma who received Nivolumab, Ipilimumab or Dabrafenib plus Trametinib therapy between January 2010 - March 2021 and had follow-up at our clinic. Response rates, survival times and side effects associated with each of the three treatment arms were evaluated. Nivolumab, Ipilimumab and Dabrafenib plus Trametinib were compared with regard to effectiveness and tolerability. Results: The Nivolumab, Ipilimumab and Dabrafenib plus Trametinib treatment arms, included 34 (58.6%), 13 (22.4%) and 11 (19%) patients, respectively. The comparison of Nivolumab, Ipilimumab and Dabrafenib plus Trametinib yielded, respectively; ORR (53%, 38.5%, 72.8%), mPFS (7 months, 3 months, 9 months) (p=0.57), mOS (12 months, 16 months, 15 months) (p=0.85). Conclusion: In this study that we conducted with real life data, we confirmed that Nivolumab, Ipilimumab and Dabrafenib plus Trametinib have different effectiveness adn manageable side effect profiles in the treatment of advanced malignant melanoma. Keywords: Dabrafenib plus trametinib, malignant melanoma, nivolumab, ipilimumab

---

Cite This Article

Kalkan Z, Ebinc S, Urakci Z, Oruc Z, İıleri S, Tunc S, Kucukoner M, Kaplan M, Isikdogan A. Evaluation of Immunotherapy and Targeted Therapies in the Treatment of Metastatic Malignant Melanoma. EJMI. 2022; 6(4): 429-435

Corresponding Author: Ziya Kalkan

Full Text PDF PDF Download